This paper answers a major concern of manufacturers: Do x-rays affect the quality and efficacy of a drug during product inspection?
USP is developing new guidelines to help organizations prioritize risk and ensure raw material quality.
A General Chapter on mAbs will be published in USP-NF as biologics increase their role in healthcare.
Assessing risk factors is key to implementing the new ICH Q3D guidelines for elemental impurities.
Assessing risk factors is key to implementing the new ICH Q3D guidelines for elemental impurities.
Assessing risk factors is key to implementing the new ICH Q3D guidelines for elemental impurities.
Assessing risk factors is key to implementing the new ICH Q3D guidelines for elemental impurities.
Assessing risk factors is key to implementing the new ICH Q3D guidelines for elemental impurities.
Assessing risk factors is key to implementing the new ICH Q3D guidelines for elemental impurities.
The results of an industry workgroup’s examination of EMA’s guide on shared facilities are presented.
Assessing risk factors is key to implementing the new ICH Q3D guidelines for elemental impurities.
Assessing risk factors is key to implementing the new ICH Q3D guidelines for elemental impurities.
Several chromatographic resins are available for downstream purification.
The pharmaceutical manufacturing platforms of fluid-bed granulation and milling are widely used to modify particle size. However, the adoption of process analytical technology to monitor and control these processes is difficult because of their dynamic nature. This study examines the efficacy of a particle characterizing technology to capture particle images under dynamic conditions and to calculate particle size distribution data both in-line and at-line during fluid-bed granulation and milling.
The pharmaceutical manufacturing platforms of fluid-bed granulation and milling are widely used to modify particle size. However, the adoption of process analytical technology to monitor and control these processes is difficult because of their dynamic nature. This study examines the efficacy of a particle characterizing technology to capture particle images under dynamic conditions and to calculate particle size distribution data both in-line and at-line during fluid-bed granulation and milling.
The pharmaceutical manufacturing platforms of fluid-bed granulation and milling are widely used to modify particle size. However, the adoption of process analytical technology to monitor and control these processes is difficult because of their dynamic nature. This study examines the efficacy of a particle characterizing technology to capture particle images under dynamic conditions and to calculate particle size distribution data both in-line and at-line during fluid-bed granulation and milling.
The pharmaceutical manufacturing platforms of fluid-bed granulation and milling are widely used to modify particle size. However, the adoption of process analytical technology to monitor and control these processes is difficult because of their dynamic nature. This study examines the efficacy of a particle characterizing technology to capture particle images under dynamic conditions and to calculate particle size distribution data both in-line and at-line during fluid-bed granulation and milling.
A case study describes how a software control system can manage training needs across an international company and improve GMP compliance.
Companies manufacturing cytotoxic drugs must ensure that staff are given the highest possible levels of protection.
In-silico design facilitates process optimization and evaluation of process control strategies.
In-silico design facilitates process optimization and evaluation of process control strategies.
An analysis of controlled correspondence between generic-drug manufacturers and FDA reveals patterns in questions about specific drug chemistry topics and the response to information provided in FDA guidance documents.
In-silico design facilitates process optimization and evaluation of process control strategies.
In-silico design facilitates process optimization and evaluation of process control strategies.
Advancement of emerging therapies faces hurdles across all aspects and phases of drug development and manufacturing.